Results of a survey on the treatment of adolescents and young adult (AYA) sarcoma patients in Spain at present time

• Cristina Mata Fernández ^[3] ; Nacho Gutierrez Carrasco ^[1] ; Antonio Juan Ribelles ^[4] ; Nadia Hindi Muñiz ^[5] ; Anna Estival González ^[6] ; Alba Rubio San Simón ^[7] ; Lucía Castillo Portellano ^[8] ; Sofía Ruiz Medina ^[2] ; Claudia Valverde Morales ^[9]
  1. [1] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  2. [2] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  3. [3] Hospital Universitario Materno Infantil Gregorio Marañón, Unidad de Oncología y Hematología Pediátricas y del Adolescente, Madrid, España
  4. [4] Hospital Universitario y Politécnico La Fe, Valencia, España
  5. [5] Hospital Fundación Jiménez Díaz , Madrid, España
  6. [6] Instituto Catalán de Oncología, ICO., Badalona, España
  7. [7] Hospital Infantil Niño Jesús, Madrid, España
  8. [8] Hospital Virgen de las Nieves, Granada, España
  9. [9] Hospital Universitario Vall d´Hebron, Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 12 (December), 2022, págs. 2475-2479
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction We aimed to analyse health care services for adolescents and young adults (AYA) with sarcomas in Spain.

    Methods A survey was sent to all Spanish cancer centres, including questions about demographic, facilities, and treatment strategies for AYAs with sarcomas in the last 2 years.

    Results Thirty-five units participated in the survey, 17 paediatric and 15 adult units. There were three specialized AYA units. First line regimen varied depending on whether the treating unit was paediatric or not, for osteosarcomas, rhabdomyosarcomas, and non-rhabdomyosarcomas. By contrast, 91.4% of Ewing sarcomas were treated according to EE2012. In the relapse setting, differences between units were higher in all tumours. Additionally, 48% of the units reported not having trials for this population.

    Conclusion There are major differences in the treatment of AYAs with sarcomas between adult and paediatric units. Enormous efforts are needed to homogenize treatments and increase the access to innovation.